Member Info for Laura2022

Rlydian

Yes, BOTAK and others the most obvious

Now above 7p

Nearly 100% up in a eek ln COIN

Northern Standard Limited 422,727,272 19.67%

First Equity Limited 179,000,000 8.33%

T and I Limited 160,000,000 7.45%

Spreadex Limited 93,050,001 4.33%

Oberon Investments Limited 80,475,000 3.74%

A Leach 80,000,000 3.72%

S Gibeon 71,400,000 3.32%

J. R. Kight 56,100,000 2.61%

Rathbones Investment Management Ltd 24,835,704 1.16%

Octopus Investments 21,875,000 1.02%

Vulpes Investment Management Pte Ltd 20,554,191 0.96%

Seneca Partners Limited 16,301,456 0.76%

Buying again is good today

6.4/6.9

May 2025

TheraCryf*

CDMO/CRO selected to progress Orexin-1 programme

Theracryf has announced that it has secured a master services agreement (MSA) with

Pharmaron UK, a leading contract research organisation (CRO), to progress development of

TCF’s Orexin-1 (Ox-1) addiction programme. Under the agreement, Pharmaron will support

the completion of the remaining pre-clinical data required to enable a clinical trial authorisation

(IND/CTA) application. This work will include manufacturing scale-up, formulation

development, clinical trial drug supply, and regulatory-compliant toxicology studies –

representing the final stages of pre-clinical development before human trials begin. As

previously outlined during TCF’s recent £4.25m equity fundraise, a significant portion of the

proceeds will be directed towards advancement of the Ox-1 programme. Activities under the

MSA are expected to begin imminently, with updates to be provided at the start and conclusion

of each work package. Full completion of the studies necessary to support the IND/CTA

submission is anticipated in the second half of 2026, which we would view as a key milestone

for the programme.

— OX1 asset: TCF’s Ox-1 asset was brought in-house following the acquisition of Chronos Therapeutics

(for further details see our March 2024 report). Studies have shown that Ox-1 plays an important role

across a range of neuropsychiatric conditions such as anxiety, impulse and substance use disorders,

significant markets which remain underserved by existing treatment options. Additionally, there is a

renewed positive market sentiment in neuroscience drug development, evidenced by a number of

notable M&A transactions over the past 12-18 months, including most recently J&J’s (January 2025)

$14.6bn acquisition of CNS specialist, Intra-Cellular Therapies.

— Newsflow: With the extended cash runway following the £4.25m equity fundraise completed in March

2025, TCF has almost tripled the number of potential catalytic share-price events that may materialise

over the next 6-24 months with newsflow from the development of the Ox-1 asset programme

representing the most tangible near-term inflection points. These include (i) restart of Ox-1

neuropsychiatry programme, (ii) commencement of Ox-1 manufacturing optimisation and (iii)

commencement of Ox-1 chronic toxicology studies followed by release of pre-clinical datasets.

— Investment thesis: Theracryf is delivering compelling data across multiple indications for its clinical

asset, SFX-01, and the acquired neuropsychiatry small molecules have expanded TCF’s pipeline

substantially. We believe this diversification helps to de-risk the investment thesis by shifting the

company away from the perception of being a single-asset biotech. We consider TCF’s equity thesis

to be further supported by its established clinical investigator collaborations, which will continue to

progress SFX-01,

Accord9ng to their website 80% or more of the shares are held by insiders and funds

After 3mths since the disastrous placing I've been buying some TCF

Market capitalisation is backed by cash and some interesting developments afoot in the sector

I'm fortunate to be doing well on COIN and CLAI could well follow

Very undervalued A.I medical stock is PYC

I bought at the start

Raised £500,000 with half going to directors and the rest to affiliated institutional investors

> raised at current prices (0.225p with no discount ) and only 111mln new shares quaking about 20% dilution the to the current 600mln

> after fund raise market cap will still only be c £1.4mln yet other companies (see below) show where potential market cap could go

MSTR, MTPLF, NAKA, ASST, CEP(XXI), COIN (UK), SWC (UK).

COIN = £15mln

SWC = £120mln

> These examples reinforce the Board's conviction that a disciplined Bitcoin strategy can create tangible shareholder value.

"The early success of pioneers such as Smarter Web Company and Metaplanet shows that thoughtful Bitcoin treasury management can strengthen the balance sheet and signal technological leadership. We intend to follow a similarly prudent path as we execute Cel AI's growth plans," said Olivia Edwards, Board Chair.

>Value of SOL now c20% up and worth £800,000

05 August 2024, 4,149 SOL were purchased at a price of £96.40 per token. As of Dec 2024 , the number of SOL held has increased to 4,253 with a carrying value of approximately £630,000. The price as of May 2025 is £130 per coin so an up lift of 30%  so now worth £830,000

Good morning to people

Ladt few at 0.032p then it's negotiation trade to purchase

6p+

Those who sold thinking they could buy cheaper will be annoyed

Good start

I'm already well in profit after this rise from 40p to 65p and alot of my shares bought below 46p, but 70p would be a nice ring you it

Looking forward to this week , hopefully I'll be up 100% from purchases soon

Yes Tombone

It's the 3rd or 4th along with BenNa

Stewarty

They won't, they've just returned and have 6mths

Warrie

Not a problem

Best wishes

Oh..thankyou